Recent Updates
Recently added Catalysts

EXC 001

Phase 2

Reduction in Severity of Skin Scarring | Small molecule | Dermatology |Pfizer, Inc.|Last Updated: Aug 13, 2021

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment14
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01494922Safety and Efficacy of EXC 001 in Subjects Who Have Participated in Prior Studies of EXC 001PHASE2 COMPLETED 14Dec 8, 2011Sep 10, 2013Aug 13, 20214 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Week 2 to Week 24

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included SAEs and all non-SAEs that occurred during the study.

Number of Participants With Positive Skin Sensitivity Reaction
Day 1 up to Week 24

Participants were instructed to inform the investigator in case of any itching, redness, pain or any other symptom that appeared to be a rash at the injection sites. Erythematous, raised (indurated) and edematous reactions were considered as positive skin sensitivity reactions. In this outcome measure number of participants with any positive skin sensitivity reaction were reported.

Number of Participants With Clinically Significant Findings in Laboratory Examinations
Day 1 up to Week 24

Following parameters were analyzed for laboratory examination: hematology (hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); Hepatobiliary biochemistry: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Albumin, Alkaline Phosphatase, Total Bilirubin ; Renal Function Tests: Blood Urea Nitrogen (BUN), Creatinine, Creatinine Kinase, Uric Acid ; Electrolytes: Sodium, Potassium; Glucose; Urine analysis: (decimal logarithm of reciprocal of hydrogen ion activity )\[pH\], Specific gravity. Clinically significant laboratory abnormality findings were based on investigator discretion.

Number of Participants With Clinically Significant Change in Vital Signs
Day 1 up to Week 24

Following vital sign parameters were assessed: diastolic blood pressure, systolic blood pressure, respiration rate, pulse rate, temperature and body weight. Number of participants with clinically significant change in any vital sign parameter compared to baseline were reported. Clinically significant change in vital signs criteria were based on investigator's discretion.

Number of Participants With Clinically Significant Findings in Electrocardiogram (ECG) Abnormalities
Day 1 up to Week 24

Following parameters were analyzed: heart rate, PR interval, QT interval, QRS interval and QT interval corrected using Fridericia's formula (QTcF). Clinically significant findings in ECG were based on investigator's discretion.

Number of Participants With Abnormalities in Physical Examinations
Day 1 up to Week 24

Physical examination included the assessment of skin, head, ears, eyes, nose, throat, respiratory system, cardiovascular system, abdomen (including liver and kidneys), musculoskeletal system, neurological system, gastrointestinal system, genitourinary system, endocrine system and lymph nodes. Abnormality in physical examination were based on investigator's discretion.

Secondary Endpoints
Physician Observer Scar Assessment Score: Individual Sub Scores and Composite Score
Week 24
Participant Observer Scar Assessment Score: Individual Sub Scores, Composite Score, Scar Appearance Composite Score
Week 24
Number of Scars Classified According to Physician Photonumeric Guide Score Severity Category
Week 24
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Open LabelEXPERIMENTAL -
Interventions
NameTypeDescription
EXC 001 (currently called PF-06473871)DRUGSingle dose administered by injection at four different times
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 65 Years
SexALL
Healthy VolunteersNo
Study Sites4

Inclusion Criteria: * Healthy adults who have participated in previous studies of EXC 001. * Healthy adults who have chosen to have their scars revised. Exclusion Criteria: * Currently pregnant or pregnant during the 6 months prior to inclusion in the study, or breast feeding. * Participation in ...

Countries:United States
Unlock Eligibility Criteria